20-08-2009

InterMed Discovery (IMD) announced the acquisition of unique microbial Omega-3 fatty acid production strains and related know-how from the University of Saarland. This innovative microbial source has the potential to produce Omega-3 more sustainably and reliably compared to established ...

more

18-08-2009

DxS Ltd has announced the appointment of Dr. David Jackson as Vice President of Business Development and Licensing. Dr. Jackson will be responsible for planning and executing business development efforts for the companion diagnostics and technology licensing business units of DxS and will be ...

more

11-08-2009

DxS Ltd has announced the appointment of Dave Clennell as Director of Quality. Dave has worked in Quality within the healthcare industry for 30 years and has a wealth of experience in FDA-related markets. Prior to joining DxS, Dave worked as International Director of Quality for Lombard ...

more

29-07-2009

Nabriva Therapeutics announced the initiation of a clinical Phase I trial for BC-3781, a pleuromutilin antibiotic being developed to treat serious infections including complicated skin and skin structure infections and community-acquired pneumonia. The clinical study is designed to evaluate ...

more

24-07-2009

Nabriva Therapeutics announced the initiation of a clinical Phase I trial for BC-3781, a pleuromutilin antibiotic being developed to treat serious infections including complicated skin and skin structure infections and community-acquired pneumonia. The clinical study is designed to evaluate ...

more

10-07-2009

DIREVO Industrial Biotechnology GmbH announced that it has completed the move to new premises of its own at the BioCampus Cologne. This is another important step in building up the company to figure as a major player in industrial biotechnology. It was further announced that DIREVO is ...

more

06-07-2009

BioInvent International AB and ThromboGenics NV announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follows completion of recruitment of the first cohort of 100 patients ahead of schedule. TB-402 is a novel, long acting ...

more

23-06-2009

Exosome Diagnostics, Inc. and DxS Ltd. announced that they will collaborate on the development of blood based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS’ Scorpions® real-time PCR Mutation Test Kits in conjunction with ...

more

19-06-2009

bitop AG and Activaero GmbH announced the start of a clinical study on bitop AG’s medical device Ectoin® inhalation solution using Activaero’s controlled breathing technology, the AKITA² inhalation system. Ectoin® inhalation solution is based on Ectoin®, an extremolyte, a natural substance ...

more

Offering to Provide Comprehensive Image of Individual Whole Genome

12-06-2009

Illumina, Inc. has unveiled a service program to provide high-quality personal genome sequencing for consumers. This is the first service to offer complete coverage of the human genome sequence for under $50,000. The Personal Genome Sequencing Service is performed in Illumina’s recently ...

more